Article summary
Resilient Pharmaceuticals (formerly Lykos Therapeutics and MAPS PBC), reportedly resubmitted their once-rejected New Drug Application (NDA) for MDMA-assisted therapy for PTSD to the FDA, triggering a fresh review cycle under the agency's newly finalized psychedelic clinical trial guidance. The post Psychedelic Policy Briefing 8.21.26 first appeared on Lucid News.
Continue to the original publication for the complete article.